📊 BMRA Key Takeaways
Is Biomerica Inc. (BMRA) a Good Investment?
Biomerica is a severely distressed diagnostic company with stagnant revenue ($2.6M), massive operating losses (-96.1% margin), and persistent cash burn (-$1.3M operating cash flow). Despite modest liquidity (3.25x current ratio), the company is operationally insolvent with no clear path to profitability or sustainable revenue growth.
Biomerica’s fundamentals are weak: revenue is flat, gross margin is very low at 18.4%, and operating losses are nearly as large as total revenue, indicating a business model that is not currently scaling profitably. The balance sheet is relatively clean with solid liquidity and no meaningful debt, but continued cash burn and negative free cash flow materially weaken financial durability unless revenue growth and margins improve quickly.
Why Buy Biomerica Inc. Stock? BMRA Key Strengths
- Strong current ratio of 3.25x provides near-term liquidity buffer
- Zero long-term debt reduces financial leverage risk
- Cash position of $2.5M provides runway for operations
- Strong liquidity with a 3.25x current ratio and $2.54M in cash
- Debt-free balance sheet with low financial leverage
- Net loss and EPS improved year over year, suggesting some cost or non-operating improvement
BMRA Stock Risks: Biomerica Inc. Investment Risks
- Flat revenue with zero growth trajectory indicates severe market/competitive headwinds
- Negative operating margin of -96.1% indicates business model is fundamentally broken
- Persistent operating cash burn of -$1.3M will exhaust cash reserves within 1.9 years at current rate
- Net losses of -$1.3M on only $2.6M revenue demonstrates inability to control costs
- Low gross margin of 18.4% leaves minimal buffer for operating expenses
- Negative ROE and ROA show value destruction across equity and assets
- Revenue stagnation with 0.0% year-over-year growth
- Extremely weak profitability, including a -96.1% operating margin and -50.9% net margin
- Ongoing operating and free cash flow burn could erode the cash position if losses persist
Key Metrics to Watch
- Quarterly revenue trend - any indication of stabilization or contraction acceleration
- Operating cash flow depletion rate and runway to insolvency
- Gross margin sustainability and cost structure improvements
- Cash balance trajectory and potential need for financing or restructuring
- Form 4 insider trading activity patterns - selling suggests lack of confidence
- Revenue growth acceleration and gross margin improvement
- Operating cash flow burn relative to cash on hand
Biomerica Inc. (BMRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.25x current ratio provides a solid financial cushion.
BMRA Profit Margin, ROE & Profitability Analysis
BMRA vs Healthcare Sector: How Biomerica Inc. Compares
How Biomerica Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biomerica Inc. Stock Overvalued? BMRA Valuation Analysis 2026
Based on fundamental analysis, Biomerica Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biomerica Inc. Balance Sheet: BMRA Debt, Cash & Liquidity
BMRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biomerica Inc.'s revenue has declined by 25% over the 5-year period, indicating business contraction. The most recent EPS of $-2.84 indicates the company is currently unprofitable.
BMRA Revenue Growth, EPS Growth & YoY Performance
BMRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $987.0K | $2.0K | $-0.44 |
| Q2 2026 | $1.2M | $2.0K | $-0.06 |
| Q1 2026 | $1.4M | $2.0K | $0.00 |
| Q3 2025 | $1.0M | -$950.0K | $-0.06 |
| Q2 2025 | $1.6M | -$950.0K | $-0.06 |
| Q1 2025 | $1.7M | -$1.1M | $-0.07 |
| Q3 2024 | $1.0M | -$1.1M | $-0.11 |
| Q2 2024 | $1.5M | -$1.1M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biomerica Inc. Dividends, Buybacks & Capital Allocation
BMRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biomerica Inc. (CIK: 0000073290)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BMRA
What is the AI rating for BMRA?
Biomerica Inc. (BMRA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMRA's key strengths?
Claude: Strong current ratio of 3.25x provides near-term liquidity buffer. Zero long-term debt reduces financial leverage risk. ChatGPT: Strong liquidity with a 3.25x current ratio and $2.54M in cash. Debt-free balance sheet with low financial leverage.
What are the risks of investing in BMRA?
Claude: Flat revenue with zero growth trajectory indicates severe market/competitive headwinds. Negative operating margin of -96.1% indicates business model is fundamentally broken. ChatGPT: Revenue stagnation with 0.0% year-over-year growth. Extremely weak profitability, including a -96.1% operating margin and -50.9% net margin.
What is BMRA's revenue and growth?
Biomerica Inc. reported revenue of $2.6M.
Does BMRA pay dividends?
Biomerica Inc. does not currently pay dividends.
Where can I find BMRA SEC filings?
Official SEC filings for Biomerica Inc. (CIK: 0000073290) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMRA's EPS?
Biomerica Inc. has a diluted EPS of $-0.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BMRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biomerica Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BMRA stock overvalued or undervalued?
Valuation metrics for BMRA: ROE of -29.7% (sector avg: 15%), net margin of -50.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BMRA stock in 2026?
Our dual AI analysis gives Biomerica Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BMRA's free cash flow?
Biomerica Inc.'s operating cash flow is $-1.3M, with capital expenditures of $51.0K. FCF margin is -50.6%.
How does BMRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -50.9% (avg: 12%), ROE -29.7% (avg: 15%), current ratio 3.25 (avg: 2).